MGRC was founded in 2004
and listed on the ACE Market
of Bursa Malaysia Securities in 2010.
MGRC was founded in 2004 and listed on the ACE Market of Bursa Malaysia Securities in 2010.
As a leading genomics and biopharmaceutical company in Southeast Asia, we have pioneered genome sequencing, bioinformatics analysis, genetic screening services, and cancer immunotherapy in the region.
We have an established track record of delivering on large-scale projects for the Government of Malaysia, as well as local and international research centres, public institutes, academia and corporations from pharmaceutical and various other sectors. Some notable customers have included Novartis, Brigham & Women’s Hospital (of Harvard Medical School) and Washington University of Medicine, among many others.
Our extensive experience in healthcare, especially in genomics, genetics and clinical diagnostics extends to translational medicine, which is the transferring of knowledge and technology from research domains to clinical use by doctors in clinics and hospitals.
With our high-throughput sequencing lab, advanced microarray facility and new state-of-the-art cell processing lab, we are committed to continually providing improved access to the latest immunotherapy and healthcare solutions for our customers.
Get To Know The Faces At The
Helm Of CAR T-Cell Immunotherapy
Dr Lim Teck Onn
Dr Khoo Jo Lynn, PhD
Dr Eunice Pui